Understanding Gastroesophageal Adenocarcinoma: What Pharmacists Should Know

This program was supported by Jazz Pharmaceuticals, content independence maintained by Pharmacy Times.

Matthew Arango, PharmD, specialty practice pharmacist in outpatient gastrointestinal oncology at The James Comprehensive Cancer Center at The Ohio State University Wexner Medical Center, discusses the fundamentals of gastroesophageal adenocarcinoma (GEA) and why cancers of the lower esophagus and stomach are approached as a unified disease state. In this segment, he outlines the typical patient profile and key risk factors driving the rise in GEA, including conditions such as gastroesophageal reflux disease and obesity. He also touches on the generally challenging prognosis and walks through the diagnostic steps—from early symptoms like dysphagia to the essential role of biopsy—in shaping treatment pathways.